

Vinay Prasad

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5320299/vinay-prasad-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

290
papers

5,613
citations

35
h-index

69
g-index

334
ext. papers

7,530
ext. citations

8.3
avg, IF

7.2
L-index

#	Paper	IF	Citations
290	Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. <i>JAMA Network Open</i> , 2019 , 2, e192535	10.4	382
289	Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. <i>JAMA Internal Medicine</i> , 2017 , 177, 1569-1575	11.5	206
288	A decade of reversal: an analysis of 146 contradicted medical practices. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 790-8	6.4	205
287	Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. <i>JAMA Oncology</i> , 2015 , 1, 539-40	13.4	201
286	The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. <i>JAMA Internal Medicine</i> , 2015 , 175, 1389-98	11.5	198
285	Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. <i>JAMA Internal Medicine</i> , 2015 , 175, 1992-4	11.5	188
284	Perspective: The precision-oncology illusion. <i>Nature</i> , 2016 , 537, S63	50.4	185
283	The high price of anticancer drugs: origins, implications, barriers, solutions. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 381-390	19.4	178
282	Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. <i>JAMA Oncology</i> , 2018 , 4, 1093-1098	13.4	169
281	Prespecified falsification end points: can they validate true observational associations?. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 241-2	27.4	150
280	Precision oncology: origins, optimism, and potential. <i>Lancet Oncology</i> , 2016 , 17, e81-e86	21.7	130
279	Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 11-12	19.4	117
278	Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. <i>BMC Medicine</i> , 2017 , 15, 134	11.4	112
277	Reversals of established medical practices: evidence to abandon ship. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 37-8	27.4	102
276	A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. <i>European Journal of Cancer</i> , 2019 , 106, 196-211	7.5	80
275	Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. <i>JAMA Oncology</i> , 2018 , 4, 157-158	13.4	79
274	The frequency of medical reversal. <i>Archives of Internal Medicine</i> , 2011 , 171, 1675-6		74

273	Why cancer screening has never been shown to "save lives"--and what we can do about it. <i>BMJ, The</i> , 2016 , 352, h6080	5.9	66
272	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. <i>Seminars in Oncology</i> , 2017 , 44, 132-135	5.5	64
271	Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. <i>Mayo Clinic Proceedings</i> , 2016 ,	6.4	59
270	Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. <i>JAMA Oncology</i> , 2015 , 1, 787-95	13.4	57
269	Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. <i>JAMA Oncology</i> , 2018 , 4, 994-996	13.4	57
268	An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. <i>JAMA Internal Medicine</i> , 2019 , 179, 915-921	11.5	55
267	Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. <i>JAMA Network Open</i> , 2020 , 3, e200423	10.4	52
266	A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. <i>ELife</i> , 2019 , 8,	8.9	47
265	Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1620-9	2.2	45
264	Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. <i>Journal of Clinical Epidemiology</i> , 2013 , 66, 361-366.e4	5.7	45
263	Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. <i>JAMA Internal Medicine</i> , 2019 , 179, 642-647	11.5	44
262	Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. <i>JAMA Oncology</i> , 2019 , 5, 887-892	13.4	43
261	The accelerated approval of oncologic drugs: lessons from ponatinib. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 353-4	27.4	43
260	The Use of Superlatives in Cancer Research. <i>JAMA Oncology</i> , 2016 , 2, 139-41	13.4	41
259	Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 2377-2378	27.4	39
258	Chest pain in the emergency department: the case against our current practice of routine noninvasive testing. <i>Archives of Internal Medicine</i> , 2012 , 172, 1506-9		38
257	Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings. <i>JAMA Internal Medicine</i> , 2015 , 175, 237-44	11.5	36
256	Comparative effectiveness questions in oncology. <i>New England Journal of Medicine</i> , 2014 , 370, 1478-81	59.2	34

255	The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy?. <i>JAMA Internal Medicine</i> , 2013 , 173, 493-5; discussion 495	11.5	32
254	Media coverage of medical journals: do the best articles make the news?. <i>PLoS ONE</i> , 2014 , 9, e85355	3.7	32
253	Distinctive clinical characteristics of malignant mesothelioma in young patients. <i>Oncotarget</i> , 2015 , 6, 16766-73	3.3	31
252	Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. <i>JAMA Oncology</i> , 2021 , 7, 728-734	13.4	30
251	Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. <i>JAMA Internal Medicine</i> , 2020 , 180, 1108-1115	11.5	29
250	Examining the Use of Real-World Evidence in the Regulatory Process. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 843-852	6.1	29
249	Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter. <i>JAMA Internal Medicine</i> , 2017 , 177, 425-427	11.5	28
248	Authorship Inflation in Medical Publications. <i>Inquiry (United States)</i> , 2015 , 52,	1.4	28
247	US News and World Report cancer hospital rankings: do they reflect measures of research productivity?. <i>PLoS ONE</i> , 2014 , 9, e107803	3.7	28
246	Characteristics of Exceptional or Super Responders to Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1639-49	6.4	27
245	Does the declining lethality of gunshot injuries mask a rising epidemic of gun violence in the United States?. <i>Journal of General Internal Medicine</i> , 2014 , 29, 1065-9	4	27
244	The misguided ethics of crossover trials. <i>Contemporary Clinical Trials</i> , 2014 , 37, 167-9	2.3	27
243	Real-world Evidence-What Does It Really Mean?. <i>JAMA Oncology</i> , 2019 , 5, 781-783	13.4	26
242	The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab. <i>JAMA Internal Medicine</i> , 2014 , 174, 1887-8	11.5	26
241	FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019. <i>JAMA Internal Medicine</i> , 2020 , 180, 912-914	11.5	25
240	The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era. <i>Archives of Internal Medicine</i> , 2012 , 172, 955-8		24
239	Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World. <i>JAMA Oncology</i> , 2017 , 3, 889-890	13.4	22
238	Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 271-2	27.4	21

237	Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration. <i>JAMA Internal Medicine</i> , 2016 , 176, 389-91	11.5	20
236	Industry Funding of Cancer Patient Advocacy Organizations. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1668-1670	6.4	20
235	Improving observational studies in the era of big data. <i>Lancet, The</i> , 2018 , 392, 716-717	4.0	20
234	Blood-Based Screening for Colon Cancer: A Disruptive Innovation or Simply a Disruption?. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 2519-20	27.4	19
233	Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. <i>Oncologist</i> , 2016 , 21, 261-8	5.7	19
232	Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. <i>CMAJ Open</i> , 2018 , 6, E31-E38	2.5	18
231	Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. <i>BMJ, The</i> , 2018 , 360, k668	5.9	18
230	Drugs that lack single-agent activity: are they worth pursuing in combination?. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 193-194	19.4	17
229	Non-inferiority trials: why oncologists must remain wary. <i>Lancet Oncology, The</i> , 2015 , 16, 364-6	21.7	17
228	A reality check of the accelerated approval of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 656-658	19.4	17
227	Low-value approvals and high prices might incentivize ineffective drug development. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 399-400	19.4	16
226	Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. <i>JAMA Network Open</i> , 2020 , 3, e200363	10.4	15
225	The Rising Price of Cancer Drugs-A New Old Problem?. <i>JAMA Oncology</i> , 2017 , 3, 277-278	13.4	15
224	Are we treating professionalism professionally? Medical school behavior as predictors of future outcomes. <i>Teaching and Learning in Medicine</i> , 2011 , 23, 337-41	3.4	15
223	A medical burden of proof: Towards a new ethic. <i>BioSocieties</i> , 2012 , 7, 72-87	1.5	15
222	The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 707-12	6.4	14
221	A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. <i>European Journal of Cancer</i> , 2018 , 101, 143-151	7.5	14
220	How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. <i>Blood</i> , 2015 , 126, 1860-1	2.2	14

219	Reclaiming the morbidity and mortality conference: between Codman and Kundera. <i>Medical Humanities</i> , 2010 , 36, 108-11	1.4	14
218	Considering benefit and risk before routinely recommending SpaceOAR. <i>Lancet Oncology</i> , 2021 , 22, 11-13	21.7	14
217	Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018. <i>JAMA Internal Medicine</i> , 2021 , 181, 162-167	11.5	14
216	A pooled analysis of published, basket trials in cancer medicine. <i>European Journal of Cancer</i> , 2018 , 101, 244-250	7.5	12
215	Conflicts of interest in Twitter. <i>Lancet Haematology</i> , 2017 , 4, e408-e409	14.6	12
214	Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 653-654	19.4	12
213	Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.. <i>JAMA Network Open</i> , 2021 , 4, e2138793	10.4	12
212	Effect of the American Society of Clinical Oncology's Conflict of Interest Policy on Information Overload. <i>JAMA Oncology</i> , 2016 , 2, 1653-1654	13.4	11
211	Open issues with open access publication. <i>American Journal of Medicine</i> , 2013 , 126, 563-4	2.4	11
210	The evidence landscape in precision medicine. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	11
209	What constitutes an "unmet medical need" in oncology? An empirical evaluation of author usage in the biomedical literature. <i>Seminars in Oncology</i> , 2017 , 44, 8-12	5.5	10
208	Combining drugs and extending treatment - a PFS end point is not sufficient. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 521-522	19.4	10
207	Publication trends among internal medicine residents and graduates. <i>American Journal of Medicine</i> , 2012 , 125, 939-44	2.4	10
206	The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval. <i>JAMA Oncology</i> , 2021 , 7, 1607-1609	13.4	10
205	Multiplying therapies and reducing toxicity in metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1014-8	4.6	9
204	Future jobs of FDA's haematology-oncology reviewers. <i>BMJ</i> , 2016 , 354, i5055	5.9	9
203	Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials?. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 361-3	5.7	9
202	Why randomized controlled trials are needed to accept new practices: 2 medical worldviews. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 1046-50	6.4	9

201	Double-crossed: why crossover in clinical trials may be distorting medical science. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 625-7	7.3	9
200	Clostridium difficile diarrhea and fecal transplantation. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 742-3	3	9
199	Cardiovascular primary prevention: how high should we set the bar?. <i>Archives of Internal Medicine</i> , 2012 , 172, 656-9; discussion 659		9
198	Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. <i>Lancet Oncology, The</i> , 2020 , 21, 1134-1136	21.7	9
197	Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations?. <i>JAMA Network Open</i> , 2020 , 3, e2012119	10.4	9
196	Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2479-2480	27.4	8
195	Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma. <i>Journal of Cancer Policy</i> , 2019 , 21, 100189	1	8
194	The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study. <i>CMAJ Open</i> , 2018 , 6, E57-E62	2.5	8
193	Use of the Word "Cure" in the Oncology Literature. <i>American Journal of Hospice and Palliative Medicine</i> , 2015 , 32, 477-83	2.6	8
192	Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 379-80	3	8
191	Perspective: beyond storytelling in medicine: an encounter-based curriculum. <i>Academic Medicine</i> , 2010 , 85, 794-8	3.9	8
190	The cardiovascular biomarker conundrum: challenges and solutions. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 2151-2	27.4	8
189	Can a resident's publication record predict fellowship publications?. <i>PLoS ONE</i> , 2014 , 9, e90140	3.7	8
188	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. <i>BMJ Evidence-Based Medicine</i> , 2020 ,	2.7	8
187	Precision medicine in acute myeloid leukemia: Hope, hype or both?. <i>Leukemia Research</i> , 2016 , 48, 73-7	2.7	8
186	Persistent challenges with treating multiple myeloma early. <i>Blood</i> , 2021 , 137, 456-458	2.2	8
185	Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 633-635	3.9	8
184	Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1785-1786	13.4	8

183	Choice of control group in randomised trials of cancer medicine: are we testing trivialities?. <i>Lancet Oncology, The</i> , 2018 , 19, 1150-1152	21.7	7
182	Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration. <i>JAMA Internal Medicine</i> , 2018 , 178, 743-744	11.5	6
181	A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 2303-2311	4.9	6
180	The Peltzman effect and compensatory markers in medicine. <i>Healthcare</i> , 2014 , 2, 170-172	1.8	6
179	Counterpoint: were industry-sponsored roflumilast trials appropriate? No. <i>Chest</i> , 2014 , 145, 939-42	5.3	6
178	Duty hour reform in a shifting medical landscape. <i>Journal of General Internal Medicine</i> , 2013 , 28, 1238-40		6
177	Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. <i>European Journal of Heart Failure</i> , 2016 , 18, 128-32	12.3	6
176	Multiplicity in oncology randomised controlled trials: a threat to medical evidence?. <i>Lancet Oncology, The</i> , 2019 , 20, 1638-1640	21.7	6
175	Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. <i>BMJ, The</i> , 2018 , 362, k3783	5.9	6
174	Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing. <i>European Journal of Cancer</i> , 2020 , 141, 152-161	7.5	5
173	Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?. <i>Cancer</i> , 2020 , 126, 4087-4088	6.4	5
172	Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. <i>JAMA Internal Medicine</i> , 2020 , 180, 797-799	11.5	5
171	Overestimating the Benefit of Cancer Drugs. <i>JAMA Oncology</i> , 2017 , 3, 1737-1738	13.4	5
170	Modern drug development: which patients should come first?. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 2619-20	27.4	5
169	Characteristics of cluster randomized trials: are they living up to the randomized trial?. <i>JAMA Internal Medicine</i> , 2013 , 173, 313-5	11.5	5
168	Evaluating health system processes with randomized controlled trials. <i>JAMA Internal Medicine</i> , 2013 , 173, 1279-80	11.5	5
167	But how many people died? Health outcomes in perspective. <i>Cleveland Clinic Journal of Medicine</i> , 2015 , 82, 146-50	2.8	5
166	Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 428-433	7.3	5

165	Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?. <i>European Journal of Cancer</i> , 2020 , 139, 20-26	7.5	5
164	Same Data; Different Interpretations. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3729-3732	2.2	5
163	Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. <i>JAMA Network Open</i> , 2019 , 2, e1916091	10.4	5
162	The response rate of alternative treatments for drugs approved on the basis of response rate. <i>International Journal of Cancer</i> , 2021 , 148, 713-722	7.5	5
161	Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 727-728	19.4	5
160	The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.. <i>Translational Oncology</i> , 2022 , 18, 101374	4.9	5
159	The effect of hospital visitor policies on patients, their visitors, and healthcare providers during the COVID-19 pandemic: a systematic review.. <i>American Journal of Medicine</i> , 2022 ,	2.4	5
158	Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. <i>JAMA Network Open</i> , 2019 , 2, e193981	10.4	4
157	Should Evidence Come with an Expiration Date?. <i>Journal of General Internal Medicine</i> , 2019 , 34, 1356-1357	4	4
156	Shifting, overlapping and expanding use of "precision oncology" terminology: a retrospective literature analysis. <i>BMJ Open</i> , 2020 , 10, e036357	3	4
155	Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 424-426	6.4	4
154	Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non-Small Cell Lung Cancers. <i>JAMA Network Open</i> , 2020 , 3, e202488	10.4	4
153	Assessing Pharmaceutical Research and Development Costs-Reply. <i>JAMA Internal Medicine</i> , 2018 , 178, 588-589	11.5	4
152	Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. <i>Oncologist</i> , 2016 , 21, 1031-2	5.7	4
151	Clinically meaningful benefit: real world use compared against the American and European guidelines. <i>Blood Cancer Journal</i> , 2017 , 7, 645	7	4
150	The overdiagnosis of pneumonia. <i>Cleveland Clinic Journal of Medicine</i> , 2013 , 80, 616-8	2.8	4
149	Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm. <i>Translational Oncology</i> , 2021 , 15, 101248	4.9	4
148	The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2793-2795	1.9	4

147	Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 7-8	19.4	4
146	Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?. <i>European Journal of Cancer</i> , 2018 , 104, 252-253	7.5	4
145	The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018. <i>BMC Cancer</i> , 2021 , 21, 889	4.8	4
144	A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer. <i>Trends in Cancer</i> , 2020 , 6, 736-738	12.5	3
143	Application of Medicare's New Technology Add-on Payment Program for Blinatumomab. <i>JAMA Oncology</i> , 2016 , 2, 165-6	13.4	3
142	The declining demand for hospital care as a rationale for duty hour reform. <i>Journal of General Internal Medicine</i> , 2014 , 29, 1400-3	4	3
141	The reply. <i>American Journal of Medicine</i> , 2014 , 127, e21	2.4	3
140	Statins, primary prevention, and overall mortality. <i>Annals of Internal Medicine</i> , 2014 , 160, 867-9	8	3
139	Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. <i>European Journal of Cancer</i> , 2015 , 51, 2718-23	7.5	3
138	In reply I-reversal of medical practices. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 1183-4	6.4	3
137	Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals. <i>Blood Cancer Journal</i> , 2017 , 7, 637	7	3
136	Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?. <i>Cmaj</i> , 2015 , 187, E276-E278	3.5	3
135	Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more. <i>Annals of Gastroenterology</i> , 2013 , 26, 277-278	2.2	3
134	Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2020 , 96, 106420	2.7	3
133	Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. <i>Future Science OA</i> , 2020 , 6, FSO600	2.7	3
132	Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. <i>Lancet Haematology</i> , 2021 , 8, e299-e304	14.6	3
131	ASCO Plenary Sessions: impact, legacy, future. <i>Seminars in Oncology</i> , 2016 , 43, 321-6	5.5	3
130	Overall Survival vs Disease-Specific Survival-Reply. <i>JAMA Oncology</i> , 2018 , 4, 586-587	13.4	3

129	Unanticipated Outcomes: A Medical Memoir & Book Review. <i>JAMA Internal Medicine</i> , 2018 , 178, 11	11.5	3
128	Meaningful and Accurate Disclosure of Conflict of Interest at the ASTRO National Meeting: A Need for Reassessment of Current Policies. <i>Journal of Oncology Practice</i> , 2018 , JOP1800121	3.1	3
127	How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond. <i>European Journal of Cancer</i> , 2021 , 157, 68-70	7.5	3
126	Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2021 , 139, 80-86	5.7	3
125	Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.. <i>JAMA Network Open</i> , 2022 , 5, e222265	10.4	3
124	Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method. <i>Cmaj</i> , 2019 , 191, E272-E273	3.5	2
123	Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?. <i>Pharmacoeconomics</i> , 2020 , 38, 729-731	4.4	2
122	PFO closure for secondary stroke prevention: is the discussion closed?. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 74-76	5.1	2
121	Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off?. <i>Journal of General Internal Medicine</i> , 2016 , 31, 1367-1368	4	2
120	Observational studies cannot justify the inferior vena cava filter. <i>American Journal of Medicine</i> , 2014 , 127, e15	2.4	2
119	Treatment of moderate to severe hidradenitis suppurativa. <i>Annals of Internal Medicine</i> , 2013 , 159, 72	8	2
118	Persistent reservations against the premedical and medical curriculum. <i>Perspectives on Medical Education</i> , 2013 , 2, 335-9	4.3	2
117	Limitations Concerning the Association of Physician Sex and Patient Outcomes. <i>JAMA Internal Medicine</i> , 2017 , 177, 1058	11.5	2
116	Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?. <i>Cancer</i> , 2017 , 123, 3872-3874	6.4	2
115	Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go. <i>JAMA Oncology</i> , 2017 , 3, 16-17	13.4	2
114	Caution needed when predicting problem residents. <i>Academic Medicine</i> , 2011 , 86, 2; author reply 2	3.9	2
113	Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington. <i>JAMA Internal Medicine</i> , 2020 , 180, 329-331	11.5	2
112	The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. <i>JAMA Internal Medicine</i> , 2020 , 180, 315-317	11.5	2

111	Approval and Coverage of Cancer Drugs in England, Canada, and the US. <i>JAMA Internal Medicine</i> , 2021 , 181, 509-510	11.5	2
110	Pembrolizumab for Non-Muscle-Invasive Bladder Cancer-A Costly Therapy in Search of Evidence. <i>JAMA Oncology</i> , 2021 , 7, 501-502	13.4	2
109	Registration studies - when should patients be deemed ineligible for aggressive therapy?. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 333-334	19.4	2
108	Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours. <i>Current Oncology</i> , 2019 , 26, e791-e792	2.8	2
107	Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs. <i>American Journal of Medicine</i> , 2019 , 132, 718-721	2.4	2
106	The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years. <i>JAMA Oncology</i> , 2021 , 7, 1569-1570	13.4	2
105	Has the Current Oncology Value Paradigm Forgotten Patients' Time?: Too Little of a Good Thing. <i>JAMA Oncology</i> , 2021 ,	13.4	2
104	Tebentafusp in first-line melanoma trials: An outperforming outlier.. <i>Translational Oncology</i> , 2022 , 20, 101408	4.9	2
103	Use of word "unprecedented" in the media coverage of cancer drugs: Do "unprecedented" drugs live up to the hype?. <i>Journal of Cancer Policy</i> , 2017 , 14, 16-20	1	1
102	Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 951-956	6.4	1
101	Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses. <i>American Journal of Cardiovascular Drugs</i> , 2015 , 15, 379-86	4	1
100	News Coverage of the American Cancer Society's Update to Colorectal Cancer Screening Guidelines. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 617-618	6.4	1
99	US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. <i>Cancer</i> , 2020 , 126, 4270-4272	6.4	1
98	Medical Reversals in Family Practice: A Review. <i>Current Therapeutic Research</i> , 2020 , 92, 100579	2.4	1
97	Statistical significance and clinical evidence - Authors' reply. <i>Lancet Oncology</i> , 2020 , 21, e119	21.7	1
96	Why is research in early-stage cancer research so low?. <i>Journal of Cancer Policy</i> , 2018 , 17, 4-8	1	1
95	Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1300-1301	13.4	1
94	Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply. <i>JAMA Pediatrics</i> , 2018 , 172, 701-708.3	8.3	1

93	The US Food and Drug Administration's use of pathologic complete response as regulatory endpoint: Did it pay off?. <i>Journal of Cancer Policy</i> , 2018 , 16, 49-51	1	1
92	A further strategy to combat the high price of anticancer drugs. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 629	19.4	1
91	Is "Do Everything!" Always Appropriate?-Reply. <i>JAMA Oncology</i> , 2017 , 3, 1588	13.4	1
90	It is time to stop screening for prostate cancer. <i>JAMA Internal Medicine</i> , 2014 , 174, 1841-2	11.5	1
89	Firearm legislation and gun-related fatalities. <i>JAMA Internal Medicine</i> , 2013 , 173, 2011	11.5	1
88	Baseline event rate, the Concorde fallacy, and the topography of cardiac risk. <i>Medical Hypotheses</i> , 2010 , 75, 639-41	3.8	1
87	Steroids in infection: an old wives' tale. <i>Cmaj</i> , 2011 , 183, 83; author reply 83-4	3.5	1
86	Retrospective comparative effectiveness research: will changing the analytical methods change the results?. <i>International Journal of Cancer</i> , 2022 ,	7.5	1
85	Reporting of Physicians' or Investigators' Choice of Treatment in Oncology Randomized Clinical Trials.. <i>JAMA Network Open</i> , 2022 , 5, e2144770	10.4	1
84	Powering cancer screening for overall mortality. <i>Ecancermedicalscience</i> , 2013 , 7, ed27	2.7	1
83	Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020. <i>JAMA Network Open</i> , 2021 , 4, e2135123	10.4	1
82	The apples and oranges of cost-effectiveness. <i>Cleveland Clinic Journal of Medicine</i> , 2012 , 79, 377-9	2.8	1
81	Medical reversals in low- and middle-income countries. <i>International Journal of Health Planning and Management</i> , 2020 , 35, 631-638	2.2	1
80	Response to Comment on "Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?". <i>Pharmacoeconomics</i> , 2020 , 38, 895-896	4.4	1
79	Drug repurposing in oncology - Authors' reply. <i>Lancet Oncology, The</i> , 2020 , 21, e544	21.7	1
78	Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR). <i>Mayo Clinic Proceedings</i> , 2020 , 95, 889-910	6.4	1
77	Assessment of New Molecular Entities Approved for Cancer Treatment in 2020. <i>JAMA Network Open</i> , 2021 , 4, e2112558	10.4	1
76	Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets.. <i>Journal of Cancer Policy</i> , 2021 , 28, 100283	1	1

75	Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?. <i>Medical Hypotheses</i> , 2016 , 93, 71-3	3.8	1
74	Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma. <i>JCO Oncology Practice</i> , 2021 , 17, e461-e468	2.3	1
73	Idecabtagene vicleucel: questions regarding the appropriate role and cost. <i>British Journal of Haematology</i> , 2021 ,	4.5	1
72	New drugs and options can enhance patient outcomes: But can they also erode them?. <i>European Journal of Cancer</i> , 2021 , 154, 1-3	7.5	1
71	The FDA's latest move to expand eligibility for oncology trials - a double-edged sword?. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 745-746	19.4	1
70	Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TV's <i>The Resident</i> .. <i>European Journal of Emergency Medicine</i> , 2022 , 29, 142-143	2.3	1
69	Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102904	2.2	1
68	Characteristics of oncology podcasts: Attitudes, speakers, conflicts.. <i>Journal of Cancer Policy</i> , 2022 , 32, 100329	1	1
67	Inconsistent Reporting of Potential Conflicts of Interest. <i>JAMA Internal Medicine</i> , 2018 , 178, 1424-1425	11.5	0
66	Long-term effects of the 2003 ACGME resident duty hour reform on hospital mortality. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 1023-5	6.4	0
65	Regarding empiricism and rationalism in medicine and 2 nd medical worldviews. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 137	6.4	0
64	Emphasizing unique strengths and eliminating redundancy for research in low-income and middle-income countries: Lessons from a South American country. <i>Cancer</i> , 2015 , 121, 2668-70	6.4	0
63	An unmeasured harm of screening. <i>Archives of Internal Medicine</i> , 2012 , 172, 1442-3		0
62	The accelerated approval pathway in oncology: Balancing the benefits and potential harms.. <i>Journal of Cancer Policy</i> , 2022 , 32, 100323	1	0
61	The frequency of assessment of progression in randomized oncology clinical trials. <i>Cancer Reports</i> , 2021 , e1527	1.5	0
60	Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. <i>Cancer</i> , 2021 , 128, 311	6.4	0
59	Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020.. <i>Journal of Cancer Policy</i> , 2021 , 30, 100311	1	0
58	Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100149	1.4	0

57	The regulatory saga of fedratinib. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 27, 1248-1250	1.7	○
56	Accurate accounting of caplacizumab cost effectiveness. <i>Lancet Haematology</i> , 2021 , 8, e315	14.6	○
55	Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13580	4.6	○
54	Reply to Dr. Leon: true but unrelated. <i>Journal of Clinical Epidemiology</i> , 2016 , 75, 127	5.7	○
53	Drug Approvals in Hepatocellular Carcinoma-Filling the Nonexistent Gap?. <i>JAMA Oncology</i> , 2021 , 7, 173-174	13.4	○
52	Inconsistent Reporting of Potential Conflicts of Interest. <i>JAMA Oncology</i> , 2018 , 4, 1439	13.4	○
51	An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	○
50	Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. <i>European Journal of Cancer</i> , 2021 , 155, 163-167	7.5	○
49	Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review. <i>JAMA Network Open</i> , 2021 , 4, e2124728	10.4	○
48	Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COVS.2.S vaccination. <i>Frontiers of Medicine</i> , 2021 , 1	12	○
47	Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021 , 156, 164-174	7.5	○
46	Where are randomized trials necessary: Are smoking and parachutes good counterexamples?. <i>European Journal of Clinical Investigation</i> , 2021 , e13730	4.6	○
45	Accelerated approval requirements for lurbinectedin.. <i>Lancet Oncology, The</i> , 2022 , 23, e206	21.7	○
44	Multiplicity: When Many Analytic Plans Are Applied or Many Redundant Studies are Run, False Positive Results are Ensured.. <i>European Journal of Clinical Investigation</i> , 2022 , e13802	4.6	○
43	Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials.. <i>JAMA Network Open</i> , 2022 , 5, e2212327	10.4	○
42	Pricing and Value of Cancer Drugs--Reply. <i>JAMA Oncology</i> , 2015 , 1, 842-3	13.4	
41	In Reply--Is There a Need for "Bias Police" in Industry-Sponsored Research?. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 121	6.4	
40	Inconsistent Reporting of Potential Conflicts of Interest. <i>JAMA Pediatrics</i> , 2018 , 172, 886	8.3	

39	Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesn't?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1353-7	4.9
38	Rebuttal from Dr Rho et al. <i>Chest</i> , 2014 , 145, 943-4	5.3
37	Response. <i>Chest</i> , 2015 , 148, e31-e32	5.3
36	The reply. <i>American Journal of Medicine</i> , 2013 , 126, e45	2.4
35	Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. <i>Oncologist</i> , 2015 , 20, 1344-6	5.7
34	Further thoughts on why there are good data supporting the inferior vena cava filter. <i>JAMA Internal Medicine</i> , 2014 , 174, 164-5	11.5
33	The reply. <i>American Journal of Medicine</i> , 2014 , 127, e15	2.4
32	Taking care of sick patients. <i>Cmaj</i> , 2013 , 185, 1008	3.5
31	Why resident physicians stay late. <i>Cmaj</i> , 2013 , 185, 1184	3.5
30	Routine noninvasive testing and highly sensitive troponin immunoassays--reply. <i>JAMA Internal Medicine</i> , 2013 , 173, 833-4	11.5
29	The inferior vena cava filter--reply. <i>JAMA Internal Medicine</i> , 2013 , 173, 1754-5	11.5
28	Perspective: Why There Must Be a Meditative Medicine. <i>Alternative and Complementary Therapies</i> , 2011 , 17, 274-278	0.3
27	Raise the bar even higher for primary prevention interventions-reply. <i>Archives of Internal Medicine</i> , 2012 , 172, 1352-3	
26	Freedom to innovate: the perils of centralized medical research-reply. <i>Archives of Internal Medicine</i> , 2012 , 172, 1692-3	
25	Holiday reading: The facts are the facts. <i>Cmaj</i> , 2012 , 184, 2029-30	3.5
24	An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).. <i>BMC Cancer</i> , 2022 , 22, 70	4.8
23	Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021 ,	4.5
22	Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements?. <i>Translational Oncology</i> , 2021 , 15, 101273	4.9

21	Artificial intelligence and magnetic resonance imaging may not make cancer screening better.. <i>Journal of Cancer Policy</i> , 2022 , 31, 100314	1
20	A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers.. <i>Journal of Cancer Policy</i> , 2022 , 31, 100319	1
19	Disease specific productivity of american cancer hospitals. <i>PLoS ONE</i> , 2015 , 10, e0121233	3.7
18	The conundrum of cost-effectiveness. <i>Cleveland Clinic Journal of Medicine</i> , 2012 , 79, 610-1	2.8
17	A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 19-22	5.1
16	Concerning survival signal for eltrombopag in MDS/AML. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1002-1003	1.9
15	N of 1 Data Sharing: The Impact of Data Sharing within the Hematology-Oncology Drug Products Division of the US FDA. <i>Trends in Cancer</i> , 2021 , 7, 395-399	12.5
14	Multiple myeloma triplet therapies: baseline characteristics and control groups. <i>Lancet, The</i> , 2021 , 397, 1620-1621	4.0
13	Balancing Accelerated Approval for Drugs With Accelerated Withdrawal--Reply. <i>JAMA Internal Medicine</i> , 2016 , 176, 567	11.5
12	Recommendation Reversals in Gastroenterology Clinical Practice Guidelines.. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022 , 5, 98-99	0.5
11	Moving Precision Oncology Forward Amid Myths and Misconceptions-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1790	13.4
10	Addendum: Low-value approvals and high prices might incentivize ineffective drug development. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 787	19.4
9	Old-fashioned Intelligence Will Always Be Needed in Medicine. <i>European Urology Focus</i> , 2021 , 7, 685-686	5.1
8	After COVID-19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems. <i>International Journal of Cancer</i> , 2021 , 149, 1723-1724	7.5
7	The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2305-2308	6.4
6	The Kardashian Index: a study of researchers' opinions on twitter 2014-2021. <i>Scientometrics</i> , 2022 , 127, 1923-1930	3
5	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours.. <i>European Journal of Cancer</i> , 2022 , 164, 95-104	7.5
4	Post-protocol therapy and informative censoring in the CANDOR study.. <i>Lancet Oncology, The</i> , 2022 , 23, e97	21.7

- 3 An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough?. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 161-167 7.3
- 2 FDA precedents in drug approvals: Contradiction in promoting more treatment options.. *European Journal of Cancer*, **2022**, 169, 123-125 7.5
- 1 General payments from Biogen to U.S. physicians between 2015 and 2020. *Journal of the American Geriatrics Society*, 5.6